AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37993666 — intervention group
Group type: COMPARATOR
Intervention: Home-based group (same exercises done at home)
Number of subjects: 32
Study 37993676 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-Cup
Number of subjects: 101
Study 37993676 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-Stem
Number of subjects: 101
Study 37993676 — intervention group
Group type: COMPARATOR
Intervention: Control-Cup
Number of subjects: 101
Study 37993676 — intervention group
Group type: COMPARATOR
Intervention: Control-Stem
Number of subjects: 101
Study 37993786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 406
Study 37993786 — intervention group
Group type: COMPARATOR
Intervention: Sham (inactive) electrical stimulation
Number of subjects: 406
Study 37993786 — intervention group
Group type: EXPERIMENTAL
Intervention: TTNS
Number of subjects: 406
Study 37993786 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 406
Study 37993831 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbicide exposure (measured through biomarkers of herbicide concentration)
Number of subjects: 2000
Study 37993837 — intervention group
Group type: EXPERIMENTAL
Intervention: Alberta Infant Motor Scale (AIMS)
Number of subjects: 139
Study 37993837 — intervention group
Group type: EXPERIMENTAL
Intervention: Peabody Developmental Motor Scales-2 (PDMS-2)
Number of subjects: 139
Study 37993844 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 101
Study 37993844 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study 37993889 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg levetiracetam twice daily for 14 days
Number of subjects: 84
Study 37993889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 37993961 — intervention group
Group type: EXPERIMENTAL
Intervention: TASK intervention
Number of subjects: 20
Study 37993963 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct emmetropia with focus-out glasses (DEFOG)
Number of subjects: 160
Study 37993963 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 160
Study 37993984 — intervention group
Group type: EXPERIMENTAL
Intervention: e-CBT program for 9 weeks
Number of subjects: 59
Study 37994400 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 3499
Study 37994538 — intervention group
Group type: EXPERIMENTAL
Intervention: ABHR applied directly to gloved hands
Number of subjects: 641
Study 37994538 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 641
Study 37994538 — intervention group
Group type: COMPARATOR
Intervention: Gold standard
Number of subjects: 641
Study 37994553 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (3.75 mg/day) monotherapy
Number of subjects: 6002
Study 37994553 — intervention group
Group type: COMPARATOR
Intervention: DAPT with aspirin (81-100 mg/day) and prasugrel (3.75 mg/day)
Number of subjects: 6002
Study 37994646 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 20
Study 37994980 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol plasma clearance (CL)
Number of subjects: 85
Study 37994980 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR above age-specific thresholds
Number of subjects: 85
Study 37994989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) 1 g/day for 10 weeks
Number of subjects: 20
Study 37994989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 37995070 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir (800 mg every 12 hours for 5 days)
Number of subjects: 193
Study 37995070 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 193
Study 37995070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 37995129 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE program
Number of subjects: 115
Study 37995129 — intervention group
Group type: COMPARATOR
Intervention: MBCC
Number of subjects: 115
Study 37995129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 115
Study 37995325 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC+β-TCP
Number of subjects: 94
Study 37995325 — intervention group
Group type: COMPARATOR
Intervention: β-TCP only
Number of subjects: 94
Study 37995381 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 9
Study 37995506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissolve DCB
Number of subjects: 247
Study 37995506 — intervention group
Group type: COMPARATOR
Intervention: Resolute DES
Number of subjects: 247
Study 37995609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative frontal EEG monitoring during Isoflurane effect-site concentrations of 0.7 to 0.8
Number of subjects: 828
Study 37995609 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-POD)
Number of subjects: 828
Study 37995847 — intervention group
Group type: EXPERIMENTAL
Intervention: ELF scores
Number of subjects: 136
Study 37995967 — intervention group
Group type: EXPERIMENTAL
Intervention: DiabeText messaging intervention
Number of subjects: 740
Study 37995967 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 740
Study 37996071 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant-specific IgA antibody response at 1 month after booster vaccination
Number of subjects: 2
Study 37996071 — intervention group
Group type: COMPARATOR
Intervention: Infection status (Infected vs Uninfected)
Number of subjects: 2
Study 37996099 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Nicotine Metabolite Ratio (NMR)
Number of subjects: 252
Study 37996099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette trials
Number of subjects: 252
Study 37996099 — intervention group
Group type: COMPARATOR
Intervention: Water trials
Number of subjects: 252
Study 37996121 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term exercise prehabilitation programme
Number of subjects: 12
Study 37996236 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped and collaborative care model (SCCM) with screening and psychosomatic-psychiatric consultations for distressed patients (phase II)
Number of subjects: 2200
Study 37996236 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) with screening but without consequences (phase I, main comparator)
Number of subjects: 2200
Study 37996236 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) without screening for distress (phase 0)
Number of subjects: 2200
Study 37996238 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ECG monitoring (14+14 days of continuous ECG monitoring 3 months apart using an ECG patch device)
Number of subjects: 3262
Study 37996238 — intervention group
Group type: COMPARATOR
Intervention: Standard ECG monitoring (48±24 hours of continuous ECG monitoring)
Number of subjects: 3262
Study 37996266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PC)
Number of subjects: 372
Study 37996266 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VC)
Number of subjects: 372
Study 37996266 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 372
Study 37996507 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX/bevacizumab + irinotecan
Number of subjects: 0
Study 37996507 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX/bevacizumab
Number of subjects: 0
Study 37996557 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz, 3000 pulses per session)
Number of subjects: 42
Study 37996557 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 42
Study 37996557 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 42
Study 37996653 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoliquiritigenin (ISO)
Number of subjects: 143
Study 37996653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ISO with visceral adipose tissue (VAT) and other NAFLD-related variables
Number of subjects: 143
Study 37996653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of ISO
Number of subjects: 143
Study 37996787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0 µg/kg) in Group A-Y
Number of subjects: 114
Study 37996787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0 µg/kg) in Group A-O
Number of subjects: 114
Study 37996787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg) in Group B
Number of subjects: 114
Study 37996787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg) in Group C
Number of subjects: 114
Study 37996787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/kg)
Number of subjects: 114
Study 37996787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg)
Number of subjects: 114
Study 37996787 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate (RT)
Number of subjects: 114
Study 37996787 — intervention group
Group type: COMPARATOR
Intervention: Control (no Dexmedetomidine)
Number of subjects: 114
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 5 mg
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 10 mg
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 20 mg
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 30 mg
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 40 mg
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 60 mg
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 80 mg
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 20 mg under fasted condition
Number of subjects: 62
Study 37996817 — intervention group
Group type: EXPERIMENTAL
Intervention: AD16 20 mg under fed condition
Number of subjects: 62
Study 37996817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 37996898 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural blockade (TEB)
Number of subjects: 1026
Study 37996898 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral blockade (PVB)
Number of subjects: 1026
Study 37996898 — intervention group
Group type: EXPERIMENTAL
Intervention: TEB
Number of subjects: 1026
Study 37996898 — intervention group
Group type: COMPARATOR
Intervention: PVB
Number of subjects: 1026
Study 37996906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power short-duration (HPSD) ablation using Smart Touch Surround Flow (STSF) catheter (power set at 50 W)
Number of subjects: 100
Study 37996906 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation using Smart Touch (ST) catheter (power set at 30 to 35 W)
Number of subjects: 100
Study 37996955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel CPS during LAAC
Number of subjects: 240
Study 37996955 — intervention group
Group type: COMPARATOR
Intervention: LAAC without Sentinel CPS
Number of subjects: 240
Study 37997056 — intervention group
Group type: EXPERIMENTAL
Intervention: behavSMS
Number of subjects: 9027
Study 37997056 — intervention group
Group type: EXPERIMENTAL
Intervention: behavSMS+video
Number of subjects: 9027
Study 37997056 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9027
Study 37997062 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter informing GP practices of the PLEASANT trial results
Number of subjects: 90583
Study 37997062 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 90583
Study 37997062 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 90583
Study 37997387 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dialectical behavior therapy (DBT)
Number of subjects: 240
Study 37997387 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment cognitive performance
Number of subjects: 240
Study 37997684 — intervention group
Group type: EXPERIMENTAL
Intervention: WeFlow-JAAA endograft system
Number of subjects: 15
Study 37997749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 75
Study 37997800 — intervention group
Group type: EXPERIMENTAL
Intervention: ACBMNCs infusion
Number of subjects: 0
Study 37997800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37997800 — intervention group
Group type: EXPERIMENTAL
Intervention: Angptl7 treatment
Number of subjects: 0
Study 37997800 — intervention group
Group type: COMPARATOR
Intervention: LPS group
Number of subjects: 0
Study 37999656 — intervention group
Group type: EXPERIMENTAL
Intervention: PET myocardial blood flow (MBF) quantification at 12 months post-transplant
Number of subjects: 74
Study 37999656 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy
Number of subjects: 74
Study 37999656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound examination
Number of subjects: 74
Study 37999672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (tVNS) at 20 Hz, 1 mA below discomfort threshold, delivered for 1 hour daily over 2 months.
Number of subjects: 26
Study 37999672 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (ear lobe), n = 14.
Number of subjects: 26
Study 37999672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (tVNS)
Number of subjects: 26
Study 37999708 — intervention group
Group type: EXPERIMENTAL
Intervention: HighLife Trans-Septal Mitral Valve Replacement (TSMVR) system
Number of subjects: 30
Study 37999854 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab
Number of subjects: 0
Study 37999854 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy plus placebo followed by adjuvant placebo
Number of subjects: 0
Study 37999936 — intervention group
Group type: EXPERIMENTAL
Intervention: PROXY (8-week psychological internet-delivered treatment)
Number of subjects: 5
Study 37999939 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (PER) 4 mg per day
Number of subjects: 0
Study 37999939 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 1000 mg per day
Number of subjects: 0
Study 37999939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37999939 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel (PER)
Number of subjects: 0
Study 37999939 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 0
Study 37999953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Number of subjects: 231
Study 37999953 — intervention group
Group type: COMPARATOR
Intervention: Insomnia Education Website (IEW)
Number of subjects: 231
Study 37999958 — intervention group
Group type: EXPERIMENTAL
Intervention: ChatGPT (group A)
Number of subjects: 50
Study 37999958 — intervention group
Group type: COMPARATOR
Intervention: Standard web-based tools (group B)
Number of subjects: 50
Study 37999982 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic burden assessed using the Anticholinergic Cognitive Burden scale (ACB) and Drug Burden Index (DBI) scale
Number of subjects: 255
Study 37999982 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing approach
Number of subjects: 255
Study 38000051 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive mastectomy group
Number of subjects: 63
Study 38000051 — intervention group
Group type: COMPARATOR
Intervention: Conventional mastectomy group
Number of subjects: 63
Study 38000061 — intervention group
Group type: EXPERIMENTAL
Intervention: RM score ≥ 100
Number of subjects: 40
Study 38000061 — intervention group
Group type: COMPARATOR
Intervention: RM score < 100
Number of subjects: 40
Study 38000061 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort with RM score ≥ 100
Number of subjects: 40
Study 38000061 — intervention group
Group type: COMPARATOR
Intervention: Overall cohort with RM score < 100
Number of subjects: 40
Study 38000068 — intervention group
Group type: EXPERIMENTAL
Intervention: ClassIntra
Number of subjects: 755
Study 38000068 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaafarani
Number of subjects: 755
Study 38000068 — intervention group
Group type: EXPERIMENTAL
Intervention: SAS
Number of subjects: 755
Study 38000074 — intervention group
Group type: EXPERIMENTAL
Intervention: wTN staging model based on T stage and N stage weights
Number of subjects: 0
Study 38000074 — intervention group
Group type: EXPERIMENTAL
Intervention: wTN staging model
Number of subjects: 0
Study 38000343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity chemotherapy (n=53), Intensive chemotherapy (n=6)
Number of subjects: 59
Study 38000564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 52
Study 38000564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 38000696 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiethnic Black (ME/B) participants
Number of subjects: 744
Study 38000696 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerto Rican Black Latinx participants
Number of subjects: 744
Study 38000696 — intervention group
Group type: COMPARATOR
Intervention: African American (AA/B) participants
Number of subjects: 744
Study 38000815 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium intake measured by 24-hour urinary potassium in individuals with moderate risk of hyperkalaemia.
Number of subjects: 962
Study 38000815 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium intake measured by 24-hour urinary potassium in individuals with high risk of hyperkalaemia.
Number of subjects: 962
Study 38000815 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium intake measured by 24-hour urinary potassium in individuals with low risk of hyperkalaemia.
Number of subjects: 962
Study 38000818 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF with 5% rice bran
Number of subjects: 200
Study 38000818 — intervention group
Group type: COMPARATOR
Intervention: Locally produced RUTF (active control)
Number of subjects: 200
Study 38000822 — intervention group
Group type: EXPERIMENTAL
Intervention: Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Number of subjects: 0
Study 38000822 — intervention group
Group type: EXPERIMENTAL
Intervention: IC3 assessment integrated within a larger prospective observational longitudinal clinical trial
Number of subjects: 0
Study 38000822 — intervention group
Group type: EXPERIMENTAL
Intervention: IC3 assessment
Number of subjects: 0
Study 38000826 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-cohort study involving repeat testing of child faeces for enteric pathogens.
Number of subjects: 0
Study 38000871 — intervention group
Group type: EXPERIMENTAL
Intervention: Drone-delivered AED
Number of subjects: 211
Study 38000996 — intervention group
Group type: EXPERIMENTAL
Intervention: High waist circumference group
Number of subjects: 80
Study 38001050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin (hs-cTn) assays
Number of subjects: 238
Study 38001050 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTn-based strategies
Number of subjects: 238
Study 38001145 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss prediction models using six machine learning methods
Number of subjects: 327
Study 38001145 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression modeling approach
Number of subjects: 327
Study 38001145 — intervention group
Group type: EXPERIMENTAL
Intervention: Web application for weight change prediction
Number of subjects: 327
Study 38001232 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized hip braces based on 3D scanner measurements worn for 7 days
Number of subjects: 19
Study 38001309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep time (hours/day)
Number of subjects: 854
Study 38001309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic steatosis index
Number of subjects: 854
Study 38001309 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat distribution
Number of subjects: 854
Study 38001309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle markers
Number of subjects: 854
Study 38001309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep time
Number of subjects: 854
Study 38001310 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution T1 MRI data analyzed with FreeSurfer software
Number of subjects: 50
Study 38001403 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal relationships (positive and negative experiences)
Number of subjects: 22
Study 38001403 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual model of interplay between suicidal experiences, psychosis, and interpersonal relationships
Number of subjects: 22
Study 38001403 — intervention group
Group type: EXPERIMENTAL
Intervention: Themes of interpersonal relationship dynamics
Number of subjects: 22
Study 38001403 — intervention group
Group type: EXPERIMENTAL
Intervention: Insights into interpersonal relationships and suicidal experiences
Number of subjects: 22
Study 38001461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand reflexology
Number of subjects: 60
Study 38001461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculosis (TB)
Number of subjects: 1226
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tuberculosis mycobacterium (NTM) infection
Number of subjects: 1226
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent tuberculosis infection (LTBI)
Number of subjects: 1226
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyltransferase-2 (NAT2) phenotypes in TB
Number of subjects: 1226
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyltransferase-2 (NAT2) phenotypes in NTM
Number of subjects: 1226
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyltransferase-2 (NAT2) phenotypes in LTBI
Number of subjects: 1226